Calliditas Therapeutics AB
| NASDAQ: CALT | Healthcare / Drug Manufacturers / Sweden |
| 18.43 | -0.5800 | -3.05% | Vol 47.05K | 1Y Perf 29.06% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 18.40 | ASK | 20.24 | ||
| Open | 19.28 | Previous Close | 19.01 | ||
| Pre-Market | - | After-Market | 18.41 | ||
| - - | -0.02 -0.11% |
| Target Price | 56.00 | Analyst Rating | Strong Buy 1.33 | |
| Potential % | 203.85 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 45.87 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 51.35 | Earnings Rating | — | |
| Market Cap | 548.96M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.17 | |
| Beta | 1.55 |
Today's Price Range 18.2019.28 | 52W Range 10.8225.64 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 15.44% | ||
| 1 Month | 3.54% | ||
| 3 Months | 2.73% | ||
| 6 Months | -19.17% | ||
| 1 Year | 29.06% | ||
| 3 Years | -21.31% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -30.98 | |||
ROE last 12 Months | -63.16 | |||
ROA (5Y Avg) | -14.76 | |||
ROA last 12 Months | -38.20 | |||
ROC (5Y Avg) | -89.75 | |||
ROC last 12 Months | -47.51 | |||
Return on invested Capital Q | -0.77 | |||
Return on invested Capital Y | -16.24 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -7.20 | ||||
| 7.11 | ||||
| 15.00 | ||||
| - | ||||
| -9.90 | ||||
| -2.47 | ||||
| 7.36 | ||||
| 2.53 | ||||
| 453.15M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.20 | ||||
| 4.40 | ||||
| 0.39 | ||||
| 0.64 | ||||
| -88.80 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 98.20 | ||||
| -162.60 | ||||
| -162.60 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 35.94M | ||||
| 1.21 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.25 | -0.33 | -32.00 |
| Q01 2023 | -0.57 | -0.67 | -17.54 |
| Q04 2022 | -0.47 | -0.01 | 97.87 |
| Q03 2022 | -0.84 | -0.03 | 96.43 |
| Q02 2022 | -0.97 | -0.74 | 23.71 |
| Q01 2022 | -0.47 | -0.85 | -80.85 |
| Q04 2021 | -0.79 | -0.95 | -20.25 |
| Q03 2021 | -0.84 | 0.05 | 105.95 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.22 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 47.05K |
| Shares Outstanding | 29.79K |
| Shares Float | 19.38M |
| Trades Count | 481 |
| Dollar Volume | 890.83K |
| Avg. Volume | 11.55K |
| Avg. Weekly Volume | 19.42K |
| Avg. Monthly Volume | 7.30K |
| Avg. Quarterly Volume | 7.95K |
Calliditas Therapeutics AB (NASDAQ: CALT) stock closed at 18.43 per share at the end of the most recent trading day (a -3.05% change compared to the prior day closing price) with a volume of 47.05K shares and market capitalization of 548.96M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 34 people. Calliditas Therapeutics AB CEO is Renée Aguiar-Lucander.
The one-year performance of Calliditas Therapeutics AB stock is 29.06%, while year-to-date (YTD) performance is 8.41%. CALT stock has a five-year performance of %. Its 52-week range is between 10.82 and 25.64, which gives CALT stock a 52-week price range ratio of 51.35%
Calliditas Therapeutics AB currently has a PE ratio of -7.20, a price-to-book (PB) ratio of 7.11, a price-to-sale (PS) ratio of 15.00, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -38.20%, a ROC of -47.51% and a ROE of -63.16%. The company’s profit margin is -%, its EBITDA margin is -162.60%, and its revenue ttm is $35.94 Million , which makes it $1.21 revenue per share.
Of the last four earnings reports from Calliditas Therapeutics AB, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. Calliditas Therapeutics AB’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Calliditas Therapeutics AB is Strong Buy (1.33), with a target price of $56, which is +203.85% compared to the current price. The earnings rating for Calliditas Therapeutics AB stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Calliditas Therapeutics AB has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Calliditas Therapeutics AB has a Buy technical analysis rating based on Technical Indicators (ADX : 8.62, ATR14 : 1.04, CCI20 : 218.32, Chaikin Money Flow : -0.04, MACD : 0.04, Money Flow Index : 60.15, ROC : 14.32, RSI : 58.86, STOCH (14,3) : 77.51, STOCH RSI : 0.82, UO : 50.76, Williams %R : -22.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Calliditas Therapeutics AB in the last 12-months were:
Calliditas Therapeutics AB
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
CEO: Renée Aguiar-Lucander
Telephone: +46 84113005
Address: Kungsbron 1, C8, Stockholm SE-111 22, , SE
Number of employees: 34
TipRanks News for CALT
Mon, 21 Aug 2023 11:20 GMT Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT) and Regeneron (REGN)
- TipRanks. All rights reserved.
